Abstract
Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes. Similar to gemfibrozil, clofibrate, another fibrate drug, also inhibited the expression of iNOS. Inhibition of human iNOS promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS. Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS. Gemfibrozil induced peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha. However, DeltahPPAR-alpha was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha. The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors. The combination of interleukin (IL)-1beta and IFN-gamma induced the activation of NF-kappaB, AP-1, C/EBPbeta, and GAS but not that of ISRE, suggesting that IRF-1 may not be involved in cytokine-induced expression of iNOS in human astrocytes. Interestingly, gemfibrozil strongly inhibited the activation of NF-kappaB, AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells. These results suggest that gemfibrozil inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.
Highlights
Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase in human U373MG astroglial cells and primary astrocytes
The human inducible nitric-oxide synthase (iNOS) promoter contains consensus sequences for the binding of transcription factors, including interferon-␥ (IFN-␥) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to ␥-activation site (GAS), nuclear factor-B (NF-B), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein  (C/EBP); we investigated the effect of gemfibrozil on the activation of these transcription factors
Since gemfibrozil potently inhibited the expression of iNOS in human U373MG astroglial cells, we examined the effect of gemfibrozil on cytokine-induced expression of iNOS in human primary astrocytes
Summary
Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes. Gemfibrozil strongly inhibited the activation of NF-B, AP-1, and C/EBP but not that of GAS in cytokine-stimulated astroglial cells These results suggest that gemfibrozil inhibits the induction of iNOS probably by inhibiting the activation of NF-B, AP-1, and C/EBP and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases. Reporter gene assays reveal that gemfibrozil inhibited cytokine-induced activation of NF-B, AP-1, and C/EBP but not that of GAS These results raise the possibility that gemfibrozil, a common lipid-lowering drug, may be of therapeutic value in human neuroinflammatory diseases
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have